SOX9 also drives prostate cancer development through WNT pathway activation; treatment of SOX9-expressing prostate cancers with a WNT synthesis inhibitor reduces WNT pathway signaling and tumor growth in murine xenograft models [304]. The gene discussed is SOX9; the disease is Familial prostate cancer.